Journal
BRITISH JOURNAL OF CANCER
Volume 103, Issue 11, Pages 1657-1662Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6605963
Keywords
ovarian cancer recurrence; CA-125; physical exam; vaginal cytology; imaging; follow-up
Categories
Funding
- Women's Cancer Research Foundation
Ask authors/readers for more resources
BACKGROUND: The purpose of this study was to evaluate the number of ovarian cancer and primary peritoneal cancer (PPC) progressive disease cases identified via routine follow-up procedures and the corresponding cost throughout a 16-year period at a single medical institution. METHODS: Previously undiagnosed epithelial ovarian (n = 241), PPC (n = 23), and concurrent ovarian and uterine (n = 24) cancer patients were treated and then followed via CA-125, imaging (e. g., CT scan, chest X-ray), physical examination and vaginal cytology. RESULTS: In the group of 287 patients, there were 151 cases of disease progression. Serial imaging detected the highest number of progressive disease cases (66 initial and 45 confirmatory diagnoses), but the cost was rather high ($13 454 per patient recurrence), whereas CA-125 testing (74 initial and 20 corroborative diagnoses) was the least expensive ($3924) per recurrent diagnosis. The total cost of surveillance during the 16-year period was nearly $2 400 000. CONCLUSION: Ultimately, serial imaging and the CA-125 assay detected the highest number of ovarian cancer and PCC progressive disease cases in comparison to physical examination and vaginal cytology, but nevertheless, all of the procedures were conducted at a considerable financial expense. British Journal of Cancer (2010) 103, 1657-1662. doi:10.1038/sj.bjc.6605963 www.bjcancer.com Published online 2 November 2010 (C) 2010 Cancer Research UK
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available